Trials / Completed
CompletedNCT00723359
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), and Safety of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Biotest Pharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BT062 | biologic |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-07-28
- Last updated
- 2013-07-18
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00723359. Inclusion in this directory is not an endorsement.